IgG-based CD3×FcRH5 bispecific T-cell engager (RO7187797) that binds FcRH5 on myeloma plasma cells and CD3 on T cells to redirect cytotoxic T-cell killing.
IgG-based bispecific antibody that binds FcRH5 on myeloma plasma cells and CD3 on T cells, bringing them into proximity to activate T cells and redirect cytotoxic killing of FcRH5-expressing tumor cells.
Bispecific antibody binds FcRH5 on tumor cells and CD3 on T cells, forming an immune synapse that activates T cells to release perforin/granzymes and kill FcRH5-expressing cells.
Human IgG1κ monoclonal antibody targeting CD38; induces ADCC, CDC, and apoptosis of CD38+ cells and depletes CD38+ immunosuppressive cells. Administered subcutaneously in this trial for CD38-expressing PEL/PBL and KSHV-associated MCD.
Unconjugated human IgG1κ monoclonal antibody against CD38; binding to CD38 on malignant and immunosuppressive cells induces apoptosis and immune effector–mediated killing (ADCC, ADCP, CDC), depleting CD38+ tumor cells and CD38+ regulatory cells to enhance anti-tumor immunity.
Binds CD38 on target cells; Fc engagement triggers ADCC, ADCP, and CDC, and can induce direct apoptosis of CD38+ cells.
Autologous, gene-modified CD19-directed CAR T-cell therapy; patient T cells are lentivirally transduced (3rd-generation vector, FMC63 scFv), rapidly manufactured (~17–20 h), and infused. CD19 engagement activates T cells to proliferate and kill CD19+ B cells.
Autologous T cells are lentivirally engineered to express a CD19-directed CAR (FMC63 scFv; third-generation). Upon binding CD19 on B cells, CAR signaling activates and expands the T cells, leading to targeted lysis of CD19-positive malignant (and normal) B cells through perforin/granzyme release and cytokine-mediated cytotoxicity.
CD19-directed CAR-T cells bind CD19 on target cells and induce killing via T-cell cytotoxicity (perforin/granzyme-mediated apoptosis and related immune effector mechanisms).
Anti-CD30 antibody–drug conjugate delivering MMAE, a microtubule inhibitor, to CD30-expressing cells.
Anti-CD30 monoclonal antibody linked via a cleavable valine–citrulline linker to monomethyl auristatin E (MMAE). After binding CD30 on tumor cells and internalization, the linker is proteolytically cleaved to release MMAE, which inhibits tubulin polymerization, causing G2/M arrest and apoptosis in CD30-positive cells.
Anti-CD30 ADC binds CD30, is internalized, linker is cleaved to release MMAE, which inhibits tubulin polymerization causing G2/M arrest and apoptosis of CD30+ cells.
Anti-HER2 monoclonal antibody that blocks HER2 signaling and mediates antibody-dependent cellular cytotoxicity (ADCC).
Humanized anti-HER2 monoclonal antibody that binds HER2 (ErbB2) to inhibit HER2 signaling and dimerization, suppressing proliferation of HER2-overexpressing tumor cells, and engages Fc receptors to trigger antibody-dependent cellular cytotoxicity (ADCC).
Trastuzumab binds HER2 on target cells and engages Fcγ receptors on immune effector cells (e.g., NK cells) to mediate antibody-dependent cellular cytotoxicity; it also blocks HER2 signaling, which can promote apoptosis.